VTGN - VistaGen Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
VTGN price evolution
VTGN
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $126.56 | $37.61 | ||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $128.11 | $39.08 | ||
| Long term investments | ||||
| Property, plant & equipment | $2.38 | $2.49 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.95 | $3.12 | ||
| Total investments | ||||
| Total assets | $131.07 | $42.2 | ||
| Current liabilities | ||||
| Accounts payable | $1.74 | $1.3 | ||
| Deferred revenue | $3.66 | $2.57 | ||
| Short long term debt | $0.54 | $0.52 | ||
| Total current liabilities | $4.16 | $2.91 | ||
| Long term debt | $1.72 | $1.86 | ||
| Total noncurrent liabilities | $3.62 | $3.64 | ||
| Total debt | $2.25 | $2.38 | ||
| Total liabilities | $7.78 | $6.55 | ||
| Shareholders' equity | ||||
| Retained earnings | -$346.69 | -$340.34 | ||
| Other shareholder equity | ||||
| Total shareholder equity | $123.28 | $35.65 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.64 | $68.14 | $103.11 | $1.36 |
| Short term investments | ||||
| Net receivables | $0.27 | $0.04 | $0.04 | |
| Inventory | ||||
| Total current assets | $17.51 | $71 | $104.12 | $1.58 |
| Long term investments | ||||
| Property, plant & equipment | $2.77 | $3.08 | $3.59 | $3.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.58 | $3.65 | $4.16 | $4.19 |
| Total investments | ||||
| Total assets | $21.09 | $74.64 | $108.28 | $5.77 |
| Current liabilities | ||||
| Accounts payable | $2.47 | $2.76 | $0.84 | $1.84 |
| Deferred revenue | $3.03 | $2.8 | $3.91 | $1.42 |
| Short long term debt | $0.59 | $0.43 | $0.37 | $0.37 |
| Total current liabilities | $4.57 | $5.77 | $4.19 | $2.77 |
| Long term debt | $2.13 | $2.61 | $3.35 | $3.72 |
| Total noncurrent liabilities | $4.44 | $4.16 | $12.11 | $8.73 |
| Total debt | $2.72 | $3.04 | $3.72 | $4.09 |
| Total liabilities | $9.01 | $9.93 | $16.3 | $11.5 |
| Shareholders' equity | ||||
| Retained earnings | -$326.85 | -$267.6 | -$219.84 | -$201.91 |
| Other shareholder equity | $0.03 | |||
| Total shareholder equity | $12.08 | $64.72 | $91.98 | -$5.73 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.28 | |||
| Cost of revenue | ||||
| Gross Profit | $0.28 | |||
| Operating activities | ||||
| Research & development | $3.85 | |||
| Selling, general & administrative | $3.21 | |||
| Total operating expenses | $7.06 | |||
| Operating income | -$6.78 | |||
| Income from continuing operations | ||||
| EBIT | -$6.59 | |||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$6.59 | |||
| Income (for common shares) | -$6.59 | |||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | -$0.23 | $1.11 | $1.09 | $1.09 |
| Cost of revenue | ||||
| Gross Profit | -$0.23 | $1.11 | $1.09 | $1.09 |
| Operating activities | ||||
| Research & development | $44.38 | $35.41 | $12.48 | $13.37 |
| Selling, general & administrative | $14.66 | $13.48 | $6.55 | $7.43 |
| Total operating expenses | $59.04 | $48.89 | $19.02 | $20.8 |
| Operating income | -$59.27 | -$47.78 | -$17.93 | -$20.8 |
| Income from continuing operations | ||||
| EBIT | -$59.24 | -$47.76 | -$17.93 | -$20.8 |
| Income tax expense | $0.01 | $0 | $0 | $0 |
| Interest expense | -$0.03 | |||
| Net income | ||||
| Net income | -$59.25 | -$47.76 | -$17.93 | -$20.77 |
| Income (for common shares) | -$59.25 | -$48.71 | -$42.32 | -$22.04 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$6.35 | -$6.59 | -$6.9 | -$12.23 |
| Operating activities | ||||
| Depreciation | $0.14 | $0.14 | $0.14 | $0.14 |
| Business acquisitions & disposals | -$0.53 | |||
| Stock-based compensation | $0.51 | $0.58 | $0.57 | $0.6 |
| Total cash flows from operations | -$4.54 | -$6.19 | -$7.89 | -$7.47 |
| Investing activities | ||||
| Capital expenditures | -$0.03 | |||
| Investments | ||||
| Total cash flows from investing | -$0.03 | -$0.53 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $93.52 | $34.96 | $1.08 | -$0.08 |
| Net borrowings | -$0 | -$0.78 | -$0.2 | -$0.31 |
| Total cash flows from financing | $93.52 | $34.18 | $0.88 | -$0.4 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $88.95 | $27.99 | -$7.02 | -$8.4 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$59.25 | -$47.76 | -$17.93 | -$20.77 |
| Operating activities | ||||
| Depreciation | $0.53 | $0.71 | $0.12 | $0.1 |
| Business acquisitions & disposals | -$0.53 | |||
| Stock-based compensation | $3.34 | $3.48 | $2.31 | $3.82 |
| Total cash flows from operations | -$49.72 | -$45.26 | -$12.07 | -$15.76 |
| Investing activities | ||||
| Capital expenditures | -$0.21 | -$0.2 | -$0.28 | |
| Investments | ||||
| Total cash flows from investing | -$0.74 | -$0.2 | -$0.28 | -$0.28 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.01 | $10.49 | $114.48 | $4.31 |
| Net borrowings | -$1.04 | -$0 | -$0.38 | -$0.3 |
| Total cash flows from financing | -$1.04 | $10.48 | $114.1 | $4.01 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$51.5 | -$34.97 | $101.75 | -$11.75 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.75 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |